API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Under the terms of the definitive agreement, PDL BioPharma will sale three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK Funding, LLC a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH).
Lead Product(s): Deoxycholic Acid
Therapeutic Area: Nutrition and Weight Loss Product Name: Kybella
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SWK Holdings Corporation
Deal Size: $4.3 million Upfront Cash: $4.3 million
Deal Type: Divestment August 31, 2020